Investigational New Drug (IND) Application
An Investigational New Drug application is the submission that allows an unapproved drug to be shipped and given to humans in a study, taking effect by default unless FDA imposes a clinical hold.
Federal law bars interstate shipment of an unapproved drug, and the IND is the exemption that makes human study lawful. The submission carries chemistry and manufacturing information, pharmacology and toxicology sufficient to justify the proposed exposure, prior human experience, the protocol and an investigator brochure. It is not granted. Thirty days after receipt it takes effect automatically unless FDA imposes a clinical hold, which it may do for unreasonable subject risk, unqualified investigators or an inadequate dossier.
The categories matter when reading a claim. A commercial IND is held by a sponsor developing a product, an investigator-initiated IND by a single researcher, and an expanded access IND supplies patients outside a trial without being designed to show efficacy. Once active, an IND carries continuing duties: annual reports, and expedited reporting of unexpected serious suspected adverse reactions, fastest for fatal or life-threatening events.
What an active IND establishes is narrow but real: a defined protocol, an identified sponsor, ethics review, adverse event reporting, and manufacturing described to a regulator. It establishes nothing about efficacy. Conversely, human use of a research peptide outside an IND carries no reporting obligation at all, which is why the adverse event record for grey-market compounds is empty rather than reassuring.
The phrase to distrust is IND-approved, which is not a status that exists. Sellers also quote an IND number as though it attached to the molecule, when it covers one protocol run by one sponsor and confers nothing on material sold to anyone else. Distributing a compound for research while the surrounding copy discusses human use is the situation the exemption was written to exclude.